Peter Marocco, an official who oversaw the dismantling of the U.S. Agency for International Development (USAID), has exited the State Department, according to the Trump administration.

Peter Marocco left his role as Director of the Office of Foreign Assistance, a position in which he oversaw severe cutbacks and layoffs to the agency known as USAID, the State Department said.

While the Trump administration has claimed that it would preserve the US Agency for International Development (USAID) “lifesaving and strategic aid programming”, the dismantling of the world’s biggest ...

The President Trump-appointed official who oversaw the dismantling of USAID has abruptly left his role after less than three months in the job, a senior US official has said. Pete Marocco had been ...

WSJ’s Shelby Holliday breaks down why President Trump and Elon Musk have targeted USAID, the DC-based international aid organization with more than 10,000 employees and relief operations around ...

President Donald Trump's administration has moved to fire nearly all USAID staff, as billionaire Elon Musk’s Department of Government Efficiency has slashed funding and dismissed contractors ...

Over the weekend, however, at least 42 of those programs were informed that USAID had canceled their contracts, which provided funding for the delivery of aid services over a set period of time.

Trump administration has moved to fire nearly all USAID staff Marocco may have been pushed out of role Cuts have thrown humanitarian efforts into turmoil April 13 (Reuters) - Pete Marocco ...

whilst simultaneously resources for these countries such as those from the U.S. Agency for International Development (USAID) (of which DRC was previously a major recipient) are being stripped.

A senior State Department official who masterminded the dismantling of the U.S. Agency for International Development (USAID) has left his role after less than three months, a U.S. official said.

The future of USAID – the world's largest donor of humanitarian aid, including projects to raise the quality and safety of medicines in low- and middle-income countries – is in doubt.